MARECHALE CAPITAL PLC

Investors see a 7.45% rise in Marechale Capital (MAC.L), topping a 52‑week high and outperforming peers like Neoterra, Seed Innovations, and Fusion Antibodies.

Sharp 10.48% plunge in Marechale Capital shares signals volatile sector, but a 13% recent rebound may offer a buying opportunity for savvy investors.